Samoĭlovich E O, Ermolovich M A, Kotova I F, Svirchevskaia E Iu, Shimanovich V P, Kozhemiakin A K, Protas I I, Fel'dman E V
Zh Mikrobiol Epidemiol Immunobiol. 2007 Mar-Apr(2):24-31.
The ten-years experience of acute flaccid paralysis (AFP) surveillance in Belarus has been summarized. Among 456 AFP cases reported from 1996 to 2005, 11 were classified as vaccine-associated paralytic poliomyelitis (VAPP), 445--as non-polio AFP. The risk of VAPP for the period 1996-2001 was 1 case per 745,000 used doses of oral poliovaccine (OPV). For the recipients of OPV the risk was 1 case per 911,700 doses and for the first-dose recipients--1 case per 96,000 doses. The high incidence of VAPP was a reason for implementation of sequential polio vaccination schedule in 2000. Guillain-Barre syndrome dominated among non-polio AFP (39.3% of cases); more rare were traumatic neuritis (27.9% of cases), transient monoparalysis (12.1%), myelitis (7.6%). Non-polio AFP differed from VAPP by following epidemiological and virological characteristics: predominance of previously repeatedly vaccinated against poliomyelitis; development of paralysis in long-term period after vaccination; isolation of non-polio viruses belonged to three serotypes of Coxsackie B viruses (B1, B4, B6) and six serotypes of Echo viruses (6, 7, 11, 14, 24, 25) in 8.1% of cases; absence of typical for polio residual paralyses in patients who excreted vaccine polioviruses.
白俄罗斯急性弛缓性麻痹(AFP)监测十年经验总结如下。1996年至2005年报告的456例AFP病例中,11例被归类为疫苗相关麻痹型脊髓灰质炎(VAPP),445例为非脊髓灰质炎AFP。1996 - 2001年期间VAPP的风险为每745,000剂口服脊髓灰质炎疫苗(OPV)使用量中有1例。对于OPV接种者,风险为每911,700剂中有1例,对于首剂接种者,风险为每96,000剂中有1例。VAPP的高发病率是2000年实施序贯脊髓灰质炎疫苗接种计划的原因。格林 - 巴利综合征在非脊髓灰质炎AFP中占主导(39.3%的病例);较罕见的是创伤性神经炎(27.9%的病例)、短暂性单瘫(12.1%)、脊髓炎(7.6%)。非脊髓灰质炎AFP与VAPP在以下流行病学和病毒学特征方面存在差异:既往多次接种脊髓灰质炎疫苗者居多;接种疫苗后较长时间出现麻痹;8.1%的病例中分离出属于柯萨奇B组病毒三种血清型(B1、B4、B6)和埃可病毒六种血清型(6、7、11、14、24、25)的非脊髓灰质炎病毒;排出疫苗脊髓灰质炎病毒的患者无典型的脊髓灰质炎残留麻痹。